Meeting
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunologic landscape in solid tumors expressing leukocyte immunoglobulin-like receptor B2 (LILRB2).
Authors
Sandra Jones
University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, FL
Sandra Jones , Harris Benjamin Krause , Jose Noy , Samuel A. Kareff , Asaad Trabolsi , Andrew Elliott , Alex Patrick Farrell , Balazs Halmos , Patrick C. Ma , Wafik S. El-Deiry , Ari M. Vanderwalde , Milan Radovich , George W. Sledge Jr., Gilberto Lopes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3133)
DOI
10.1200/JCO.2023.41.16_suppl.3133
Abstract #
3133
Poster Bd #
331
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunological landscape of TROP2 in solid tumors.
First Author: Asaad Trabolsi
Poster
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunological landscape of SGLT2 in lung cancer.
First Author: Heng Tan
Poster
2022 ASCO Annual Meeting
Microsatellite-stable tumors with high tumor mutational burden in association with tumor response to immune checkpoint inhibitor therapy across solid tumors and correlation with specific oncogenic alterations.
First Author: Imran Nizamuddin
Poster
2021 ASCO Annual Meeting
Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs).
First Author: Dan Rhodes